Literature DB >> 29876721

Differentiating malignant from benign hyperintense nodules on unenhanced T1-weighted images in patients with chronic liver disease: using gadoxetic acid-enhanced and diffusion-weighted MR imaging.

Ji Yoon Moon1, Seong Hyun Kim2, Seo-Youn Choi3, Jeong Ah Hwang4, Ji Eun Lee3, Jisun Lee5.   

Abstract

PURPOSE: To evaluate value of gadoxetic acid-enhanced and diffusion-weighted (DW) MRI for distinguishing malignant from benign hyperintense nodules on unenhanced T1-weighted images (T1WIs) in patients with chronic liver disease.
MATERIALS AND METHODS: Forty-two patients with 37 malignant and 41 benign hyperintense nodules on unenhanced T1WIs who underwent gadoxetic acid-enhanced and DW MRI, followed by histopathological examination, were included. Qualitative and quantitative analyses were conducted. Significant findings on univariate and multivariate analyses were identified and their diagnostic performances were analyzed for predicting hyperintense hepatocellular carcinomas (HCCs).
RESULTS: In univariate analysis, hyperintensity on T2WI, arterial enhancement, washout, hypointensity on hepatobiliary phase, and diffusion restriction were more frequently observed (P < 0.05) in hyperintense HCCs. Tumor-to-liver SI ratio on hepatobiliary phase and minimum apparent diffusion coefficient (ADCmin) were significantly lower in hyperintense HCCs (P < 0.05). In multivariate analysis, hyperintensity on T2WI (OR, 13.58; P = 0.02), arterial enhancement (OR, 8.21; P = 0.002), and ADCmin ≤ 0.83 × 10-3 mm2/s (OR, 6.88; P = 0.008) were independently significant factors for predicting hyperintense HCCs. When two of three criteria were combined, 75.7% (28/37) of hyperintense HCCs were identified with a specificity of 92.7%, and when all three criteria were satisfied, the specificity was 97.6%.
CONCLUSION: Gadoxetic acid-enhanced and DW MRI may be helpful for differentiating malignant from benign hyperintense nodules on unenhanced T1WI.

Entities:  

Keywords:  Apparent diffusion coefficient; Diffusion magnetic resonance imaging; Hepatocellular carcinoma; Magnetic resonance imaging

Mesh:

Substances:

Year:  2018        PMID: 29876721     DOI: 10.1007/s11604-018-0748-x

Source DB:  PubMed          Journal:  Jpn J Radiol        ISSN: 1867-1071            Impact factor:   2.374


  33 in total

1.  Dynamic subtraction MR imaging of the liver: advantages and pitfalls.

Authors:  Jeong-Sik Yu; Neil M Rofsky
Journal:  AJR Am J Roentgenol       Date:  2003-05       Impact factor: 3.959

2.  Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Authors:  Rita Golfieri; Matteo Renzulli; Vincenzo Lucidi; Beniamino Corcioni; Franco Trevisani; Luigi Bolondi
Journal:  Eur Radiol       Date:  2011-02-05       Impact factor: 5.315

3.  Characterization of hyperintense nodules on precontrast T1-weighted MRI: utility of gadoxetic acid-enhanced hepatocyte-phase imaging.

Authors:  Chen-Te Chou; Yao-Li Chen; Hwa-Koon Wu; Ran-Chou Chen
Journal:  J Magn Reson Imaging       Date:  2011-03       Impact factor: 4.813

4.  Spectrum of imaging findings of the liver in end-stage cirrhosis: Part II, focal abnormalities.

Authors:  G D Dodd; R L Baron; J H Oliver; M P Federle
Journal:  AJR Am J Roentgenol       Date:  1999-11       Impact factor: 3.959

5.  Hyperintense nodules on non-enhanced T1-weighted gradient-echo magnetic resonance imaging of cirrhotic liver: fate and clinical implications.

Authors:  Jeong-Sik Yu; Jei Hee Lee; Mi-Suk Park; Ki Whang Kim
Journal:  J Magn Reson Imaging       Date:  2006-09       Impact factor: 4.813

6.  Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow.

Authors:  Sachiyo Kogita; Yasuharu Imai; Masahiro Okada; Tonsok Kim; Hiromitsu Onishi; Manabu Takamura; Kazuto Fukuda; Takumi Igura; Yoshiyuki Sawai; Osakuni Morimoto; Masatoshi Hori; Hiroaki Nagano; Kenichi Wakasa; Norio Hayashi; Takamichi Murakami
Journal:  Eur Radiol       Date:  2010-05-19       Impact factor: 5.315

7.  Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

Authors:  Sung Soo Ahn; Myeong-Jin Kim; Joon Seok Lim; Hye-Suk Hong; Yong Eun Chung; Jin-Young Choi
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

8.  The hypointense liver lesion on T2-weighted MR images and what it means.

Authors:  Luís Curvo-Semedo; Jorge B Brito; Miguel F Seco; João F Costa; Cristina B Marques; Filipe Caseiro-Alves
Journal:  Radiographics       Date:  2009-11-09       Impact factor: 5.333

9.  Small hepatocellular carcinoma: relationship of signal intensity to histopathologic findings and metal content of the tumor and surrounding hepatic parenchyma.

Authors:  M Ebara; H Fukuda; Y Kojima; N Morimoto; M Yoshikawa; N Sugiura; T Satoh; F Kondo; M Yukawa; T Matsumoto; H Saisho
Journal:  Radiology       Date:  1999-01       Impact factor: 11.105

10.  Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging.

Authors:  Tejas Parikh; Stephen J Drew; Vivian S Lee; Samson Wong; Elizabeth M Hecht; James S Babb; Bachir Taouli
Journal:  Radiology       Date:  2008-01-25       Impact factor: 11.105

View more
  2 in total

Review 1.  Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Tin Nadarevic; Agostino Colli; Vanja Giljaca; Mirella Fraquelli; Giovanni Casazza; Cristina Manzotti; Davor Štimac; Damir Miletic
Journal:  Cochrane Database Syst Rev       Date:  2022-05-06

2.  Optimal Combination of Features on Gadoxetate Disodium-enhanced MR Imaging for Non-invasive Differential Diagnosis of Hepatocellular Carcinoma: The JAMP-HCC Study.

Authors:  Shintaro Ichikawa; Utaroh Motosugi; Hiroyuki Morisaka; Kazuto Kozaka; Satoshi Goshima; Tomoaki Ichikawa
Journal:  Magn Reson Med Sci       Date:  2020-02-27       Impact factor: 2.471

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.